Company Description

HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States.

The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical products.

The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021.

HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

HilleVax, Inc.

Country	United States
Founded	2020
IPO Date	Apr 29, 2022
Industry	Biotechnology
Sector	Healthcare
Employees	14
CEO	Robert Hershberg

Contact Details

Address: 321 Harrison Avenue, 5th Fl. Boston, Massachusetts 02118 United States
Phone	617 213 5054
Website	hillevax.com

Stock Details

Ticker Symbol	HLVX
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$17.00
CIK Code	0001888012
CUSIP Number	43157M102
ISIN Number	US43157M1027
SIC Code	2836

Key Executives

Name	Position
Dr. Robert M. Hershberg M.D., Ph.D.	Co-Founder, President, Chief Executive Officer and Chairman of the Board
Dr. Aditya Kohli Ph.D.	Co-Founder and Director
Shane A. Maltbie	Chief Financial Officer and Treasurer
Dr. Anju Chatterji Ph.D.	Chief Technology Officer
Paul S. Bavier J.D.	General Counsel, Secretary and Chief Administrative Officer

Latest SEC Filings

Date	Type	Title
Aug 6, 2025	SC14D9C	Filing
Aug 6, 2025	10-Q	Quarterly Report
Aug 6, 2025	8-K	Current Report
Aug 4, 2025	SC TO-C	Filing
Aug 4, 2025	SC14D9C	Filing
Aug 4, 2025	8-K	Current Report
Jul 24, 2025	SCHEDULE 13G	Filing
Jun 25, 2025	8-K	Current Report
May 8, 2025	10-Q	Quarterly Report
May 8, 2025	8-K	Current Report

View All SEC Filings